SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the utility of the PROSTest to predict response to 177 Lu-PSMA therapy in ...

SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the clinical value of the PROSTest to detect biochemical recurrence in ...

Zachary Klaassen speaks with Adrien Holzgreve about the FLEX-MRT trial, which aims to personalize lutetium-177 PSMA radioligand therapy delivery. Currently, Pluvicto™ follows fixed dosing from the ...

PSMA PET prognosis, PROMISE registry, PSMA PET survival prediction, prostate cancer prognostic biomarker, PSMA PET risk stratification, Emerging Prognostic Value of Molecular Imaging in Prostate ...

Interdisciplinary GU Cancer Forum 2025 Combination Therapies in prostate cancer, active surveillance, GG1 prostate cancer, radical prostatectomy.

Zachary Klaassen hosts Alessandro Viti to discuss early oncological outcomes in very high-risk prostate cancer patients using PSMA-PET imaging. Dr. Viti addresses the research question of how surgery ...

(UroToday.com) The 2025 ASCO annual meeting featured a prostate cancer oral abstract session and a presentation by Dr. Theodore DeWeese discussing a phase 3, randomized, placebo-controlled clinical ...

Interdisciplinary GU Cancer Forum 2025 Prostate Cancer, Artificial Intelligence in Molecular Targeted Imaging, ChatGPT by OpenAI, aPROMISE platform.

Interdisciplinary GU Cancer Forum 2025, Emerging Data and Advances in Prostate cancer Screening, Prostate cancer, homologous recombination repair (HRR), metastatic castration-resistant prostate cancer ...

Interdisciplinary GU Cancer Forum 2025, prostate cancer, de novo high-volume metastatic hormone-sensitive prostate cancer (mHSPC), Advances in Immunotherapy for prostate cancer, 177Lu-PSMA radioligand ...

Interdisciplinary GU Cancer Forum 2025, Prostate Cancer, Neoadjuvant Management of High-Risk Prostate Cancer, PROTEUS trial, GUNS trial, Genomic Umbrella Neoadjuvant Study, apalutamide, FOXA1 ...

James Wysock joins Zachary Klaassen to discuss improving prostate cancer diagnostics through better biopsy needle technology. Dr. Wysock highlights early experience with the SUREcore® Biopsy Needle ...